Watch for the Anticoagulant Bevyxxa During Transitions of Care

March 2018

You may see some patients get Bevyxxa (beh-VYKE-sah, betrixaban), a new direct oral anticoagulant (DOAC), after hospital discharge.

We know extending VTE prophylaxis after discharge is helpful for certain high-risk surgical patients...such as after hip or knee surgery.

But Bevyxxa is only for "extended-duration" PREVENTION of venous thromboembolism (VTE) in nonsurgical patients with multiple risk factors...such as reduced mobility plus older age and heart failure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote